论文部分内容阅读
目的观察经皮冠状动脉介入治疗(PCI)术前不同时间使用阿托伐他汀对术后造影剂肾病发生的影响。方法选取实施PCI术的患者120例,按术前开始使用阿托伐他汀时间(7d、8~29d、30d),将患者分为A、B、C三组,每组40例。PCI术后48h检测血肌酐(Scr)、高敏C反应蛋白(hsCRP),比较三组术后造影剂肾病的发生率。结果 PCI术后48h,三组Scr、hsCRP差异无统计学意义(P>0.05);A组造影剂肾病发生率低于C组(2.5%vs.7.5%)(P<0.05)。结论在PCI术前7d开始应用阿托伐他汀,可降低造影剂肾病发生率。
Objective To observe the effects of atorvastatin on postoperative contrast nephropathy at different time points after percutaneous coronary intervention (PCI). Methods A total of 120 patients undergoing PCI were enrolled in this study. Patients were divided into three groups (A, B and C), 40 patients in each group. The time of starting atorvastatin (7d, 8 ~ 29d, 30d) Serum creatinine (Scr) and high-sensitivity C-reactive protein (hsCRP) were measured at 48 hours after PCI. The incidence of contrast-induced nephropathy was compared between the three groups. Results There was no significant difference in Scr and hsCRP between the three groups 48h after PCI (P> 0.05). The incidence of contrast nephropathy in group A was lower than that in group C (2.5% vs.7.5%, P <0.05). Conclusions Application of atorvastatin 7 d before PCI can reduce the incidence of contrast-induced nephropathy.